A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY

Trial Profile

A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Methylprednisolone; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms STAAR
  • Sponsors Churchill Pharmaceuticals
  • Most Recent Events

    • 20 Jul 2017 Results published in a Churchill Pharmaceuticals media release.
    • 20 Jul 2017 According to a Churchill Pharmaceuticals media release, the NDA for YONSA (abiraterone acetate) ultramicrosize tablets has been accepted for filing by the US FDA. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of March 19, 2018 to complete its review.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top